Research regarding the therapeutic application of psychedelics and psychedelic-assisted psychotherapy in the treatment of eating disorders (EDs) has begun to emerge. This systematic scoping review aimed to map and synthesise the existing evidence regarding the participant reported efficacy and perspectives concerning psychedelics in the treatment of EDs, and to identify significant research...
For more than 20 years, the mainstay of pharmacologic treatment for depression and anxiety disorders has been serotonin reuptake inhibitors and selective serotonin and norepinephrine reuptake inhibitors. There are newer medications, many with novel mechanisms of action, that have come to market; however, first-line treatments remain the same. There are now more robust data on the use of various...
Psychedelic MedicineSeptember 1, 2024Banan Ramarushton, Heidemarie Blumenthal, Anthony Ryals et al.2 citations
Rumination is a well-established risk factor for the onset and maintenance of depression and anxiety and is associated with various other forms of psychopathology (e.g., eating pathology, obsessive-compulsive disorder, posttraumatic stress disorder). Evidence suggests that rumination is a transdiagnostic process that may play a key role in the comorbidity of such disorders. However, rumination...
Serotonergic psychedelics and ketamine produce rapid and long-lasting symptomatic relief in multiple psychiatric disorders. Evidence suggests that despite having distinct molecular targets, both drugs may exert therapeutic benefit via their pro-neuroplastic effects. Following treatment with ketamine or serotonergic psychedelics, patients are reported to be more open to behavioral change, which...
Stuttering poses challenges to social, occupational, and educational aspects of life. Traditional behavioral therapies can be helpful but effects are often limited. Pharmaceutical treatments have been explored but there are no FDA-approved treatments for stuttering. Interest has grown in the potential use of classic psychedelics, including psilocybin and LSD, which have shown effectiveness in...
Psychedelics have emerged as promising therapeutics for several psychiatric disorders. Hypotheses around their mechanisms have revolved around their partial agonism at the serotonin 2 A receptor, leading to enhanced neuroplasticity and brain connectivity changes that underlie positive mindset shifts. However, these accounts fail to recognise that the gut microbiota, acting via the gut-brain...
C. G. Jung wrote very little about psychedelic drugs and he took a sceptical view of them. However, he was sufficiently impressed by Aldous Huxley's 1954 account of taking mescaline, The Doors of Perception, to invite Huxley to visit him in Switzerland. Huxley declined Jung's invitation but Huxley's collaborator Humphry Osmond met Jung instead. This paper documents Jung's contact with the...
This article provides an intercultural transdisciplinary perspective on the Indigenous roots of the resurging field of psychedelic science in the management of substance use disorders (SUDs). Ritual uses of entheogens (i.e., psychedelics of natural origin) are elaborate technologies for navigating, containing, and therapeutically directing non-ordinary states of consciousness induced by these...
protocols are designed to integrate and harness the full range of ketamine's intrinsic properties, ketamine therapies can realize their full potentials [3], possibly leading to improved outcomes in broader patient populations. Our first paper, "The Montreal model: An integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression," takes this path toward...
LSD-assisted therapy may reduce anxiety, but a recent study saw adverse effects like paranoia requiring antipsychotics and overnight monitoring in one participant. Psilocybin-assisted therapy showed promise for alcohol use disorder compared to placebo, but the study also involved extensive psychotherapy which likely contributed to improvements. Psychological risks exist and must be considered...